{"id":"W4389657620","doi":"10.1016/s1474-4422(23)00403-9","title":"Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial","year":2023,"lang":"en","type":"article","venue":"The Lancet Neurology","topic":"Coagulation, Bradykinin, Polyphosphates, and Angioedema","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Alberta Hospital; Alberta Hospital Edmonton; Impact; McMaster University; Population Health Research Institute","funders":"European Stroke Organisation; Janssen Research and Development; HLS Therapeutics; Ipsen; Janssen Pharmaceuticals; Göteborgs Universitet; Deutsches Zentrum für Neurodegenerative Erkrankungen; Daiichi Sankyo Europe; Sanofi; Deutsches Zentrum für Herz-Kreislaufforschung; Sahlgrenska Universitetssjukhuset; American Stroke Association; Alexion Pharmaceuticals; Amgen; National Heart, Lung, and Blood Institute; Pfizer; Inventiva Pharma; Bristol-Myers Squibb; AstraZeneca; Novo Nordisk; American Heart Association","keywords":"Medicine; Placebo; Stroke (engine); Aspirin; Population; Clopidogrel; Risk factor; Clinical endpoint; Internal medicine; Randomized controlled trial; Anesthesia; Pathology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006759921,0.0001808857,0.0007572041,0.0002086397,0.0001325281,0.00002392613,0.0001045063,0.0001110213,0.0000936754],"category_scores_gemma":[0.000202141,0.0001216301,0.0001789268,0.0001580583,0.0001262277,0.0001026916,0.00003985638,0.0001785532,0.000004863674],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001443765,"about_ca_system_score_gemma":0.00009103161,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001609997,"about_ca_topic_score_gemma":0.00004060227,"domain_scores_codex":[0.9985459,0.0001423124,0.0005450581,0.0002833624,0.0002062021,0.0002771875],"domain_scores_gemma":[0.9981759,0.001073496,0.000366372,0.0002393468,0.00007823227,0.00006664372],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.98798,0.0001902093,0.0003534917,0.0000777721,0.0003415212,0.00001081548,0.0005468137,0.00004124323,0.002972153,0.0006555376,0.0002479458,0.006582468],"study_design_scores_gemma":[0.986932,0.002653375,0.003652676,0.00006122889,0.000316639,0.0000569109,0.00004611452,0.002957519,0.001344503,0.0002975854,0.001567715,0.0001137242],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9890165,0.0001244256,0.0006910627,0.004793467,0.0004619341,0.004334887,0.00009332858,0.00009482073,0.000389548],"genre_scores_gemma":[0.997462,0.0001257149,0.00008179663,0.0003429921,0.0007922872,0.0002757623,0.0002585615,0.00002895068,0.0006319543],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008445455,"threshold_uncertainty_score":0.4959932,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06879306530208357,"score_gpt":0.35347818787607,"score_spread":0.2846851225739864,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}